PE Anti-CD39 antibody [EPR26473-58],Abcam,AB322530
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human, Human
Application
Flow Cyt, ICC/IF, IHC-P
Conjugate
PE
Platform ID
BAB484223077
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Catalyzes the hydrolysis of nucleoside triphosphates (NTPs) and diphosphates (NDPs) (Probable) (PubMed : 8529670, PubMed : 8626624, PubMed : 8955160, PubMed : 8996251). The enzyme sequentially removes phosphate groups in two successive steps, converting NTPs to nucleoside monophosphates (NMPs) via NDP intermediates (Probable) (PubMed : 8529670, PubMed : 8626624, PubMed : 8955160, PubMed : 8996251). This activity contributes to the regulation of extracellular levels of nucleotides (Probable) (PubMed : 8529670, PubMed : 8626624, PubMed : 8955160, PubMed : 8996251). By hydrolyzing proinflammatory ATP and platelet-activating ADP to AMP, it blocks platelet aggregation and supports blood flow (PubMed : 8955160, PubMed : 8996251). See full target information ENTPD1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.